logo
    • English
      • 简体中文
      • 繁體中文
  • Home
  • Articles
    • Insights
    • Client Press Releases
    • Client Coverage
  • Interviews
    • CEO Interview
    • PDAC Interview
  • Clients
    • Featured Companies
    • In-depth Analysis
  • Markets
    • Stock Tracker
    • Markets at a glance
    • Investing 101
      • Investing in Mining 101
        • Gold and Precious Metals
        • Electric and Battery Metals
        • Base Metals
        • Other Mining Subsectors
  • METALS 100
  • GCFF Event
    • Next Event
    • Past Events
  • Home
  • Genomics
Filter

Genomics

Categories

Sectors

Locations

Exchange

Replicel Life Sciences Inc TSXV:RP Biotechnology, Medical Device, Genomics, 生物科技,医疗设备,基因组学

RepliCel Provides 2019 Year-End Update

Nov 26, 2019

医疗保健

Healthcare News Roundup

Nov 18, 2019

Life Science

Replicel Life Sciences Inc TSXV:RP Biotechnology, Medical Device, Genomics, 生物科技,医疗设备,基因组学

Replicel Provides Update to Private Placement Financing of Preferred Shares

Oct 11, 2019

Life Science

Replicel Life Sciences Inc TSXV:RP Biotechnology, Medical Device, Genomics, 生物科技,医疗设备,基因组学

RepliCel Life 751,318 shares for debt

Oct 10, 2019

Life Science

Replicel Life Sciences Inc TSXV:RP Biotechnology, Medical Device, Genomics, 生物科技,医疗设备,基因组学

Clinical Data Published from RepliCel’s Skin Rejuvenation Study

Sep 24, 2019

Life Science

Replicel Life Sciences Inc TSXV:RP Biotechnology, Medical Device, Genomics, 生物科技,医疗设备,基因组学

Replicel Closes First Tranche of Private Placement Financing of Preferred Shares

Sep 13, 2019

Life Science

Genenta Science

Genenta Science of Milan Raises $14.6 Million in Funding Led by China Investor

Sep 13, 2019

Life Science

SoliPharma

SoliPharma of Hangzhou Raises $36.5 Million to Develop High End Generics

Sep 12, 2019

Life Science

Replicel Life Sciences Inc TSXV:RP Biotechnology, Medical Device, Genomics, 生物科技,医疗设备,基因组学

RepliCel’s Partner, YOFOTO (China) Health, Unveils its Inaugural Cell Therapy Manufacturing Facility in China

Sep 11, 2019

Life Science

I-Mab

I-Mab to Test its CD73 Antibody in Combination with Junshi’s PD-1 mAb

Sep 11, 2019

Life Science

I-Mab CD73 Antibody Junshi PD-1 mAb

I-Mab to Test its CD73 Antibody in Combination with Junshi’s PD-1 mAb

Sep 11, 2019

Life Science

Replicel Life Sciences Inc TSXV:RP Biotechnology, Medical Device, Genomics, 生物科技,医疗设备,基因组学

Correction to Previous Press Release: RepliCel Life Sciences Announces Debt Settlement

Sep 10, 2019

Life Science

Eli Lilly LOXO-292(selpercatinib) RET fusion-positive non-small cell lung cancer (NSCLC)

Lilly’s $8 Billion Bet Pays Off With Dazzling Results in Lung Cancer Trial

Sep 10, 2019

Life Science

Novartis

Novartis CEO promises to speed data integrity disclosures

Sep 10, 2019

Life Science

Boehringer Ingelheim

Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound

Sep 7, 2019

Life Science

Immunotech Hong Kong IPO EAL

Beijing’s Immunotech Plans to Raise up to $200 Million in Hong Kong IPO

Sep 6, 2019

Life Science

Novartis IFM Due immunotherapies

Novartis Inks $840 Million Collaboration and Option Deal with IFM Due

Sep 6, 2019

Life Science

AstraZeneca Tagrisso (osimertinib) China

AstraZeneca’s Tagrisso Approved in China as First-Line Lung Cancer Treatment

Sep 5, 2019

Life Science

  • ‹‹ Previous
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • Next ››

We connect Investors to Opportunities.

Financial Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

 
QuoteMedia logo

Head Office

  • 2209 – 1111 Alberni Street
    Vancouver, BC Canada V6E 4V2
  • Phone: (604) 488-8878
  • Fax: (604) 488-0868
  • Toll Free: 1 (866) 833-5517
  • Email: [email protected]

Shanghai Office

  • 06 - 607, 6/f. No.800 Shangcheng
    Road Pudong New District Shanghai,
    China
  • Phone: 021-68883919
  • Fax: 021-68882879
  • Email: [email protected]

Important Links

  • Privacy Policy
  • Terms of Use
  • Content Partner
  • NAI500 Investor Relations Services
  • About Us
  • Contact Us

© 2026 NAI Interactive Ltd. All Rights Reserved

gcff

logo

Website Design Vancouver by Nirvana Canada